Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: The impacts of remission and tumour necrosis factor blockade

J. S. Smolen, C. Han, D. M F M Van Der Heijde, P. Emery, J. M. Bathon, E. Keystone, R. N. Maini, J. R. Kalden, D. Aletaha, D. Baker, J. Han, M. Bala, E. W. St Clair

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To examine the association of radiographic progression and disease activity states in patients with rheumatoid arthritis (RA) treated with methotrexate with or without infliximab. Methods: Patients (n = 1049) with active RA for 3 years or less and no previous methotrexate treatment were randomly assigned (4 : 5 : 5) to receive methotrexate plus placebo or methotrexate plus infliximab 3 or 6 mg/kg at weeks 0, 2 and 6, and every 8 weeks thereafter to week 46. Disease activity was classified by the simplified disease activity index as remission (≤3.3), low (>3.3 to ≤11), moderate (≥11 to ≤26), high (>26). Radiographic progression was measured as a change from baseline to week 54 in total Sharp score. Results: At weeks 14 and 54, more patients receiving methotrexate plus infliximab than methotrexate plus placebo were in remission (10.7% versus 2.8% week 14; 21.3% versus 12.3% week 54; p

Original languageEnglish (US)
Pages (from-to)823-827
Number of pages5
JournalAnnals of the Rheumatic Diseases
Volume68
Issue number6
DOIs
StatePublished - Jun 2009

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: The impacts of remission and tumour necrosis factor blockade'. Together they form a unique fingerprint.

Cite this